188 related articles for article (PubMed ID: 9540852)
21. Matrix metalloproteinase inhibitor CGS 27023A protects COMP and proteoglycan in the bovine articular cartilage but not the release of their fragments from cartilage after prolonged stimulation in vitro with IL-1 alpha.
Ganu V; Melton R; Wang W; Roberts D
Ann N Y Acad Sci; 1999 Jun; 878():607-11. PubMed ID: 10415786
[No Abstract] [Full Text] [Related]
22. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
[TBL] [Abstract][Full Text] [Related]
23. Coincubation of bovine synovial or capsular tissue with cartilage generates a soluble "Aggrecanase" activity.
Vankemmelbeke MN; Ilic MZ; Handley CJ; Knight CG; Buttle DJ
Biochem Biophys Res Commun; 1999 Feb; 255(3):686-91. PubMed ID: 10049771
[TBL] [Abstract][Full Text] [Related]
24. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures.
Munteanu SE; Ilic MZ; Handley CJ
Arthritis Rheum; 2000 Oct; 43(10):2211-8. PubMed ID: 11037880
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-4, an inhibitor of cartilage breakdown in bovine articular cartilage explants.
Yeh LA; Augustine AJ; Lee P; Riviere LR; Sheldon A
J Rheumatol; 1995 Sep; 22(9):1740-6. PubMed ID: 8523355
[TBL] [Abstract][Full Text] [Related]
26. A tissue-culture model of cartilage breakdown in rheumatoid arthritis. Quantitative aspects of proteoglycan release.
Steinberg J; Sledge CB; Noble J; Stirrat CR
Biochem J; 1979 May; 180(2):403-12. PubMed ID: 486116
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.
Bonassar LJ; Sandy JD; Lark MW; Plaas AH; Frank EH; Grodzinsky AJ
Arch Biochem Biophys; 1997 Aug; 344(2):404-12. PubMed ID: 9264555
[TBL] [Abstract][Full Text] [Related]
28. Kinetics of proteoglycan turnover in bovine articular cartilage explants.
von den Hoff JW; van Kampen GP; van de Stadt RJ; van der Korst JK
Matrix; 1993 May; 13(3):195-201. PubMed ID: 8326910
[TBL] [Abstract][Full Text] [Related]
29. Effects of ceramide on aggrecanase activity in rabbit articular cartilage.
Sabatini M; Thomas M; Deschamps C; Lesur C; Rolland G; de Nanteuil G; Bonnet J
Biochem Biophys Res Commun; 2001 May; 283(5):1105-10. PubMed ID: 11355886
[TBL] [Abstract][Full Text] [Related]
30. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage.
Patwari P; Gao G; Lee JH; Grodzinsky AJ; Sandy JD
Osteoarthritis Cartilage; 2005 Apr; 13(4):269-77. PubMed ID: 15780640
[TBL] [Abstract][Full Text] [Related]
31. Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokines.
Patwari P; Cook MN; DiMicco MA; Blake SM; James IE; Kumar S; Cole AA; Lark MW; Grodzinsky AJ
Arthritis Rheum; 2003 May; 48(5):1292-301. PubMed ID: 12746902
[TBL] [Abstract][Full Text] [Related]
32. Effects of free and bound insulin-like growth factors on proteoglycan metabolism in articular cartilage explants.
Tesch GH; Handley CJ; Cornell HJ; Herington AC
J Orthop Res; 1992 Jan; 10(1):14-22. PubMed ID: 1370177
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M.
Durigova M; Roughley PJ; Mort JS
Osteoarthritis Cartilage; 2008 Jan; 16(1):98-104. PubMed ID: 17574450
[TBL] [Abstract][Full Text] [Related]
34. Effects of the hydroxamic acid derivate Ro 31-4724 on the metabolism and morphology of interleukin-1-treated cartilage explants.
Steinmeyer J; Daufeldt S; Kalbhen DA
Pharmacology; 1997 Aug; 55(2):95-108. PubMed ID: 9323309
[TBL] [Abstract][Full Text] [Related]
35. Effects of proteinase inhibitors on aggrecan catabolism in chondrocyte cultures.
Flannery CR; Sandy JD
Ann N Y Acad Sci; 1994 Sep; 732():380-3. PubMed ID: 7978815
[No Abstract] [Full Text] [Related]
36. The effect of naproxen and interleukin-1 on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage in vitro.
Glazer PA; Rosenwasser MP; Ratcliffe A
J Clin Pharmacol; 1993 Feb; 33(2):109-14. PubMed ID: 8440758
[TBL] [Abstract][Full Text] [Related]
37. Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.
Kozaci LD; Brown CJ; Adcocks C; Galloway A; Hollander AP; Buttle DJ
Mol Pathol; 1998 Oct; 51(5):282-6. PubMed ID: 10193524
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines.
Tyler JA
Biochem J; 1989 Jun; 260(2):543-8. PubMed ID: 2788408
[TBL] [Abstract][Full Text] [Related]
39. A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro.
Andrews HJ; Plumpton TA; Harper GP; Cawston TE
Agents Actions; 1992 Sep; 37(1-2):147-54. PubMed ID: 1456176
[TBL] [Abstract][Full Text] [Related]
40. Independent effects of interleukin 1 on proteoglycan synthesis and proteoglycan breakdown of bovine articular cartilage in vitro.
Neidel J; Zeidler U
Agents Actions; 1993 May; 39(1-2):82-90. PubMed ID: 8285145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
